Skip to main content
Premium Trial:

Request an Annual Quote

New Products Posted to GenomeWeb: Myriad Genetics, Invitae, Seqster, More

Myriad Genetics Precise Oncology Solutions 

Myriad Genetics announced the launch of Precise Oncology Solutions, a new service through which oncologists can order its BRACAnalysis CDx and MyChoice CDx; its MyRisk Hereditary Cancer Test; and the Precise Tumor Molecular Profile Test, which is performed at a CLIA-certified lab operated by Intermountain Healthcare. Myriad and Intermountain, both headquartered in Salt Lake City, have been working on this combined offering for the past year to streamline oncologists' access to next-generation sequencing-based germline and somatic analysis, which can inform patients' inherited cancer risks and expand their personalized treatment opportunities. Doctors can order all the tests offered through this service and receive results via a new online portal. Myriad also said it will share with researchers de-identified genomic and clinical data from patients tested through this service within a new Precise Treatment Registry, powered by DNAnexus' bioinformatics platform.

Invitae Personalized Cancer Monitoring Platform 

Invitae has launched its Personalized Cancer Monitoring (PCM) platform to help detect minimal or molecular residual disease in patients with solid tumors. Invitae PCM uses a novel set of personalized assays based on a patient’s tumor to detect circulating tumor DNA in blood, enabling pan-cancer (excluding hematological malignancies) risk stratification, treatment response assessment, and cancer recurrence detection, Invitae said. Each assay is custom-designed to detect a patient's unique tumor signature, allowing for personalized results to guide treatment decisions. Invitae PCM requires both blood and tumor tissue samples from the patient to conduct tumor-normal whole-exome sequencing. Based on the results, Invitae's proprietary algorithm selects 18 to 50 tumor-specific variants to include on the patient's custom-designed ctDNA panel. Validation studies have demonstrated that the assays have greater than 99.9 percent sensitivity in detecting ctDNA at a 0.008 percent variant allele frequency, Invitae said.

Seqster Developer Portal 

Seqster said this week that it has launched the Seqster Developer Portal, allowing pharma sponsors, contract research organizations, and healthcare firms to integrate seamlessly with Seqster's patient data retrieval and delivery system.

For more new products and services, please visit the New Products page on our website.